MWMing-Gui Wang

Ming-Gui Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ming-Gui Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Jian-Qing He

    Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

    4 shared publications
  • Yu Wang

    Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

    3 shared publications
  • Miao-Miao Zhang

    Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

    2 shared publications
  • Shou-Quan Wu

    Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

    2 shared publications
  • Shouquan Wu

    Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu, Peoples R China

    2 shared publications
  • Andrew J Sandford

    Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada

    1 shared publication

Latest Publications

  • Plasma proteomics biomarkers for predicting anti‐tuberculosis drug‐induced liver injury: A comprehensive assessment

    by Ming‐Gui Wang, Meng‐Meng Zhang, Quan‐Xian Liu, Jian‐Qing He

    Aims: This study aims to identify predictive plasma protein biomarkers for anti‐tuberculosis drug‐induced liver injury (ATB‐DILI) and develop machine learning models for pre‐treatment risk stratification. Methods: In this retrospective nested case–control study, proteomic profiling of pre‐treatment plasma from 24 patients (12 ATB‐DILI, 12 controls) identified differentially expressed proteins, which were validated by ELISA in an independent cohort (35 ATB‐DILI, 37 controls). Multiple machine learning algorithms were implemented to develop clinical prediction models and evaluate the prognostic value of the identified protein biomarkers. Results: Proteomic analysis of pre‐treatment samples from the exploratory cohort identified five significantly differentially expressed proteins: antithrombin III, apolipoprotein D, carboxypeptidase B2, Chromogranin‐A, and Retinol‐binding protein 4. These proteins are functionally implicated in inflammatory responses, oxidative stress, and drug metabolism pathways. Validation using baseline plasma from an independent cohort confirmed consistent expression patterns for all five proteins ( p < 0.01), with directional changes matching the discovery phase findings. The random forest model, built on these pre‐treatment biomarkers, demonstrated robust predictive performance in the test set (AUC = 0.94, sensitivity = 90.0%, specificity = 90.0%, accuracy = 0.90). Importantly, consensus across multiple machine learning approaches (GBDT, SVM, GBM, etc.) confirmed predictive stability and generalizability of this protein signature (inter‐model AUC range: 0.85–0.96). Conclusion: This study has successfully identified five pre‐treatment plasma protein signature that, when incorporated into machine learning models, may enable the prediction of ATB‐DILI risk, offering potential for early intervention in tuberculosis therapy.


  • Open Access

    Association of Three SNPs Loci of Kelch-Like-ECH-Associated Protein 1 (Human) with Tuberculosis in Chinese Han Population

    by Shouquan Wu, Xiaojuan Ding, Qianlan Yang, Minggui Wang, Jian-Qing He

    Purpose: Progression from latent tuberculosis infection (LTBI) to pulmonary TB (PTB) was associated with genetic polymorphisms, but there were limited genetic polymorphism data on LTBI and PTB. We aimed at examining the association of KEAP1 gene polymorphisms with PTB and LTBI. Patients and Methods: PTB patients and close contacts of PTB patients were recruited from West China Hospital of Sichuan University. After obtaining the patient’s consent, we draw 2– 5mL of blood from the patient’s peripheral vein. Tag-SNPs of KEAP1 were chosen according to previous studies. The genotyping was done by improved multiplex ligase detection reaction (iMLDR). We used logistic regression to assess the association of SNPs with LTBI/PTB, with sex and age as covariates. Results: A total of 209 PTB patients, 201 LTBI, and 204 HCS were included in the present study. Three Tag-SNPs were included in this study. Significant association was found for KEAP1 rs1048290 between LTBI and HCS. Compared with the KEAP1 rs1048290 CC genotype, genotype GC had an 38% decreased risk for development LTBI (P = 0.043, OR = 0.62, 95% CI: 0.039– 0.98). We also found that SNPs in KEAP1 were significantly related to PTB compared to LTBI. Compared with the rs11545829G allele, allele A had an 30% decreased risk for development PTB (P = 0.034, OR = 0.70, 95% CI: 0.51– 0.97). We also found the rs11668429 polymorphism was related to PTB. Compared with TT, GT had a significantly increased risk of LTBI developing into PTB (P = 0.041, OR = 1.68, 95% CI: 1.02– 2.77). Conclusion: Our study suggested that KEAP1 polymorphisms were significantly related to susceptibility to PTB and LTBI subjects.

  • Abbott RealTime MTB and MTB RIF/INH assays for the diagnosis of tuberculosis and rifampicin/isoniazid resistance

    by Ming-Gui Wang, Miao Xue, Shou-Quan Wu, Miao-Miao Zhang, Yu Wang, Qianqian Liu, Andrew J. Sandford, Jian-Qing He


  • Open Access

    Association between tobacco smoking and drug-resistant tuberculosis

    by Ming-Gui Wang, Wei-Wei Huang, Yu Wang, Yun-Xia Zhang, Miao-Miao Zhang, Shou-Quan Wu, Andrew J Sandford, Jian-Qing He

    Association between tobacco smoking and drug-resistant tuberculosis Ming-Gui Wang,1,* Wei-Wei Huang,1,* Yu Wang,1 Yun-Xia Zhang,1 Miao-Miao Zhang,1 Shou-Quan Wu,1 Andrew J Sandford,2 Jian-Qing He1 1Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China; 2Centre for Heart Lung Innovation, University of British Columbia and St. Paul’s Hospital, Vancouver, BC, Canada *These authors contributed equally to this work Background: Tobacco smoking is a risk factor for tuberculosis but little is known about the relationship between tobacco smoking and drug-resistant tuberculosis (DR-TB). We undertook a systematic review and meta-analysis to quantitatively assess the association between DR-TB and tobacco smoking.Methods: We searched for relevant studies in the Ovid MEDLINE, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, WANFANG, and WEIPU databases from inception to September 1, 2017. Results were expressed as odds ratios (ORs) with accompanying 95% CIs, and subgroup analyses were performed by study design, smoking type, DR-TB type, and multivariate analysis.Results: Thirty-three studies related to tobacco smoking and DR-TB were included. We found substantial evidence that tobacco smoking is associated with an increased risk of DR-TB (OR 1.57, 95% CI 1.33–1.86). Associations were also found in subgroup analyses: for multidrug-resistant tuberculosis (OR 1.49, 95% CI 1.19–1.86) and for any DR-TB (OR 1.70, 95% CI 1.3–2.23); the pooled OR was 1.45 (95% CI 1.11–1.90) for current smoking, 2.25 (95% CI 1.46–3.47) for past smoking, and 1.56 (95% CI 1.22–1.98) for smoking history; and similar ORs were also observed in study design and multivariate analysis subgroup analysis.Conclusion: This study demonstrated that tobacco smoking is an independent risk factor for DR-TB. Keywords: tobacco smoking, drug-resistant tuberculosis, multidrug-resistant tuberculosis, MDR-TB, meta-analysis